Wall Street analysts expect Lion Biotechnologies, Inc. (NASDAQ:IOVA) to post ($0.35) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Lion Biotechnologies’ earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.38). Lion Biotechnologies reported earnings of ($0.17) per share during the same quarter last year, which would suggest a negative year over year growth rate of 105.9%. The business is scheduled to issue its next earnings results on Friday, November 3rd.

On average, analysts expect that Lion Biotechnologies will report full year earnings of ($1.42) per share for the current financial year, with EPS estimates ranging from ($1.48) to ($1.30). For the next financial year, analysts forecast that the firm will report earnings of ($1.45) per share, with EPS estimates ranging from ($1.66) to ($1.23). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Lion Biotechnologies.

Several research analysts recently commented on the company. Chardan Capital reissued a “buy” rating on shares of Lion Biotechnologies in a research report on Thursday, September 7th. HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Lion Biotechnologies in a research report on Wednesday, August 16th. Zacks Investment Research raised Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research report on Tuesday, July 18th. Cowen and Company reissued a “buy” rating on shares of Lion Biotechnologies in a research report on Wednesday, August 16th. Finally, Oppenheimer Holdings, Inc. set a $13.00 price target on Lion Biotechnologies and gave the company a “buy” rating in a research report on Monday, September 11th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Lion Biotechnologies has a consensus rating of “Buy” and an average price target of $13.88.

Shares of Lion Biotechnologies (NASDAQ:IOVA) opened at 7.45 on Thursday. The firm’s market capitalization is $532.88 million. The company has a 50-day moving average price of $5.61 and a 200 day moving average price of $6.43. Lion Biotechnologies has a 12-month low of $4.45 and a 12-month high of $8.60.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/12/brokerages-anticipate-lion-biotechnologies-inc-iova-to-announce-0-35-eps.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc acquired a new stake in shares of Lion Biotechnologies in the second quarter valued at approximately $103,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Lion Biotechnologies in the second quarter valued at approximately $125,000. People s United Financial Inc. acquired a new stake in shares of Lion Biotechnologies in the second quarter valued at approximately $143,000. Voya Investment Management LLC acquired a new stake in shares of Lion Biotechnologies in the second quarter valued at approximately $208,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Lion Biotechnologies in the second quarter valued at approximately $270,000. 66.60% of the stock is owned by institutional investors.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Get a free copy of the Zacks research report on Lion Biotechnologies (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.